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Abstract:
Introduction: Aluminum contamination of parenteral nutrition solutions has been
documented for three decades. It can result in elevated blood, bone, and whole body
aluminum levels associated with neurotoxicity, reduced bone mass and mineral content,
and perhaps hepatotoxicity. The primary aluminum source among parenteral nutrition
components is glass-packaged calcium gluconate, in which aluminum concentration the
past three decades has averaged ~ 4000 µg/L, compared to < 200 µg/L in plastic
container-packaged calcium gluconate. A concern about plastic packaging is leaching of
plasticizers, including phthalates, which have the potential to cause endocrine (male
reproductive system) disruption and neurotoxicity. Methods: Aluminum was quantified in
samples collected periodically over more than two years from three calcium gluconate
sources used to prepare parenteral nutrition solutions; two packaged in glass (from
France and the US) and one in plastic (from Germany); in a recently released plasticpackaged solution (from the US); and in the two glass containers. Phthalate
concentration was determined in selected samples of each product and leachate of the
plastic containers. Results: The initial aluminum concentration was ~ 5000 µg/L in the
two glass-packaged products and ~ 20 µg/L in the plastic-packaged product, and
increased ~ 30, 50 and 100% over 2 years, respectively. The aluminum concentration in
a recently released Calcium Gluconate Injection USP was ~ 320 µg/L. Phthalates were
not detected in any calcium gluconate solutions or leachates. Conclusion: Plastic
packaging greatly reduces the contribution of aluminum to parenteral nutrition solutions
from calcium gluconate compared to the glass-packaged product.
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What is known:


Aluminum is a contaminant of parenteral nutrition solutions.



Aluminum can cause neurotoxicity, reduced bone mass and mineral content, and
perhaps hepatotoxicity.



Glass-packaged calcium gluconate is the primary aluminum source of parenteral
nutrition solutions.

What is new:


As received glass-packaged calcium gluconate provides aluminum in excess of the
FDA’s recognized level that results in aluminum accumulation associated with
central nervous system and bone toxicity.



Aluminum in calcium gluconate increases over two years of storage.



Calcium gluconate packaged in the tested plastic containers does not provide
aluminum in excess of the FDA level or measurable phthalates (plasticizers with
potential to cause male reproductive system disruption and neurotoxicity).
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Introduction:
Aluminum contamination of parenteral nutrition solutions has been a documented
problem for three decades (1-4), which can result in elevated blood aluminum (5),
increased body burden (5, 6), increased bone aluminum (7), neurotoxicity (8), reduced
bone mass and mineral content (6, 9), and perhaps hepatotoxicity (10, 11). This led to a
US FDA labeling requirement addressing this issue, which concludes that “patients with
impaired kidney function, including premature neonates, who receive parenteral levels
of aluminum at greater than 4 to 5 [micro]g/kg/day accumulate aluminum at levels
associated with central nervous system and bone toxicity” (12). The primary source of
aluminum in parenteral nutrition solutions is calcium gluconate, reported to contribute up
to 88% vs. ~ 4% from phosphates (13), 88.7% (14), 78% to home parenteral nutrition
solutions (15), 81 vs. 9% from sodium phosphate (16), ~ 50% (17), 80% to 98% (18), 80
± 22% (19), the main source of aluminum (20), and highest amounts were provided by
dextrose and calcium gluconate (21). The raw material was identified as one, but not
the sole source (22). The aluminum primarily comes from glass packaging (23-26).
Aluminum is added to the glass of containers of parenteral solutions to improve
resistance to chemical attack and thermal shock (27).

Table 1 shows the reported concentrations of aluminum in calcium gluconate used to
prepare parenteral nutrition solutions. Most of these values indicate that the aluminum
concentration in this product, when packaged in glass, has averaged ~ 4000 µg/L, and
has not decreased over the past three decades. Excluding three high values there has
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been a non-significant increase in the aluminum concentration in calcium gluconate
packaged in glass over the past three decades (Figure 1).

The average daily administration of aluminum to premature and term infants has been
found to be 15 to 25 µg/kg (5, 39, 43, 44), or three to five times the upper boundary of
the US FDA guideline, and even higher in Argentina (21). In the United States, until mid2015, Calcium Gluconate Injection USP had only been available in glass packaging.
Pharmacists had few opportunities to minimize aluminum administration in parenteral
nutrition solutions, limited to using the most recently obtained product, based on the
assumption that the aluminum concentration increases over storage time in the glass
container (4, 45), as shown by one study cited in Table 1 (40).

A few reports have shown much less aluminum in calcium gluconate packaged in
plastic containers (Table 1) (37, 40). There have been encouragements to abandon
glass packaged calcium gluconate in favor of plastic packaging (20, 40). A concern
about plastic packaging is the possibility that the product contains leached plasticizers,
particularly phthalates such as DEHP (bis(2-ethylhexyl) phthalate, aka: di-2-ethylhexyl
phthalate, diethylhexyl phthalate). Phthalates have the potential to cause endocrine
(male reproductive system) disruption and neurotoxicity. Infants are the most
susceptible population (46, 47). Plasticizers might present a hazard not inherent to
glass containers, although the rubber stopper of glass vials could be a source.
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The present study was conducted to quantify the aluminum concentration over the shelf
life of representative calcium gluconate solutions used to prepare parenteral nutrition
solutions, and to determine the initial aluminum concentration and the rate and extent of
aluminum concentration increase over storage time. The concentration of phthalates,
including DEHP, was determined to ascertain if calcium gluconate provided a risk from
exposure to these plasticizers.
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Methods:
Multiple containers of calcium gluconate solutions used in the preparation of parenteral
nutrition solutions were obtained from three sources in July, 2013; APP
Pharmaceuticals, LLC, US, packaged in glass; C.D.M. Lavoisier, France, packaged in
glass; and B. Braun, Germany, packaged in plastic. A single vial packaged in glass was
obtained from Fresenius Kabi, LLC, US, in May, 2015. Approximately half of the 10 mL
calcium gluconate contents of individual containers from APP Pharmaceuticals and B.
Braun was clean poured into duplicate seven mL perfluoroalkoxy alkanes (PFA) vials at
~ 1.5 month intervals from July 19, 2013 through August 25, 2015. The interval between
sample transfers of the Lavoisier product was ~ every 3 months after the first three
samples. The Fresenius Kabi product was similarly transferred on September 8, 2015.
The duplicate calcium gluconate samples were analyzed by inductively coupled plasma
- mass spectrometry (ICP-MS) to quantify their aluminum concentration. The aluminum
content of one of the glass vials from APP Pharmaceuticals and one of the glass
ampoules from Lavoisier was determined by ICP-MS. Selected calcium gluconate
samples were analyzed by gas chromatography – mass spectrometry (GC-MS) to
quantify 8 phthalates. Leachable phthalates from one of the B. Braun plastic containers
and the Fresenius Kabi plastic container were determined by GC-MS. Details are
reported in the Supplemental Information.

Data analysis:
Outliers of the ICP-MS analysis of aluminum in the calcium gluconate solutions were
identified using the Grubb outlier test (http://graphpad.com/quickcalcs/Grubbs1.cfm)
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subjecting all results for samples from the same source to the test. One sample of the
Lavoisier, four samples of the B. Braun, and two water blanks were identified as outliers
and were removed from further data analysis. The average aluminum concentration of
the two-hundred fold diluted water blanks (0.45 µg/L) (S.D. = 0.14 µg/L) was subtracted
from each two-hundred fold diluted calcium gluconate value. The average aluminum
concentration of the duplicate (collected same day) samples was plotted against time,
starting with time = 0 when the first samples were transferred from their original
containers to the PFA vials (July 19, 2013). Linear regression of aluminum
concentration versus time was determined using GraphPad Prism 6 (GraphPad
Software, Inc., La Jolla, CA). The aluminum content of the glass containers was
compared by a t-test.
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Results:
Aluminum analysis:
The instrument detection limit was 0.068 µg/L aluminum. The method detection limit
(accounting for required dilution) was 13.6 µg/L aluminum. Aluminum concentration in
the two analytical duplicates was 111 and 116% of the original sample. Spike recovery
was 104 and 106% for two samples. The aluminum concentration in all samples was
greater than the instrument detection limit; the lowest was 0.29 µg/L in a water blank.
Aluminum concentration in the calcium gluconate samples is shown in Figure 2. The
slope of aluminum concentration versus time for the APP product was significantly
different from zero (F (1,15) 58.35, P < 0.0001), for the Lavoisier product was not
significantly different from zero (F (1,8) 3.75, P = 0.089), and for the B. Braun product
was (F (1,14) 15.02, P < 0.0017). The aluminum concentration in the duplicate samples
from the sole Fresenius Kabi sample collected September 8, 2015 averaged 318 µg/L.
The aluminum concentrations in the glass vial from APP Pharmaceuticals and the glass
ampoule from Lavoisier were not statistically different.

Phthalate analysis:
The blank samples had < 0.02 mg/L of the phthalates. DEHP recovery from spiked
water and Calcium Gluconate Injection USP samples was 86 and 91%, respectively.
Recovery of the other six phthalates ranged from 76 to 100% (mean = 89%). Recovery
of the surrogates ranged from 69 to 98% (mean = 89%). Recovery of p-terphenyl-d14,
that eluted closest to most of the phthalates (20.92 minutes), was 89% from water, 93%
from the Calcium Gluconate Injection USP blank, and ranged from 74 to 102% (mean =
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93%) from the eight tested samples. Recovery of the other two surrogates ranged from
69 to 98% from the blanks and 33 to 98% (mean = 80%) from the eight tested samples.
The concentrations of the seven phthalates in the eight tested one mL dichloromethane
extracts of four to five mL calcium gluconate were less than the lowest standard (0.1
mg/L), therefore there was < 0.025 mg/L phthalates in all samples. No phthalates were
detected in dichloromethane extracts of either the B. Braun or Fresenius Kabi container.
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Discussion:
The initial aluminum concentration in calcium gluconate in the APP vials and Lavoisier
ampoules was ~ 4800 µg/L (Figure 2), slightly higher than the average reported
aluminum concentration in calcium gluconate packaged in glass over the past three
decades (Figure 1). A typical initial parenteral nutrition calcium dose for neonates is 2
mEq/kg (48), which would be delivered in 4.3 mL of 10% calcium gluconate (0.465
mEq/mL Ca). 4.3 mL of 4800 µg/L aluminum would deliver ~20 µg/kg/day aluminum,
exceeding the FDA guideline of four to five µg/kg/day, and consistent with the average
daily administration of aluminum to premature and term infants of 15 to 25 µg/kg, cited
in the Introduction. The FDA’s labeling requirement that requires a statement of the
maximum level of aluminum present at expiry on the container label of small volume
parenteral drug products does not resolve the problem of aluminum contamination of
parenteral nutrition solutions. It permits aluminum concentrations in small volume
parenterals that result in aluminum concentrations in parenteral nutrition solutions in
excess of aluminum accumulation associated with central nervous system and bone
toxicity. The use of calcium gluconate solutions packaged in glass shortly after their
receipt by the end user would not successfully address the aluminum contamination
problem.

Aluminum concentration increased over time, as previously reported (40). There is a
significant slope (increase of aluminum concentration over time) for the APP product
packaged in glass, but not the Lavoisier product also packaged in glass. The increase
of aluminum in the Lavoisier product over time (~ 30%) was less than in the APP
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product (~ 50%). The Lavoisier product contained ~ 7% calcium gluconate and 3%
calcium glucoheptonate (aka gluceptate) compared to 10% calcium gluconate in the
APP product. The binding affinity of gluconate for aluminum (49) is large enough to
attribute the increase of aluminum over time in calcium gluconate to the leaching of
aluminum from the glass containers. No aluminum glucoheptonate stability constant
was found in the literature. As the structures of gluconate and glucoheptonate are very
similar there is no reason to expect a significant difference in their aluminum binding
affinities. The presence of calcium glucoheptonate in the Lavoisier product is unlikely to
account for the difference in rate of aluminum increase in these products. The amount
of aluminum in the glass vial from APP was not different from the glass ampoule from
Lavoisier (Supplemental Information). Package inserts do not inform about the type of
glass. The USP monograph for Calcium Gluconate Injection states that the solution
should be preserved in single-dose containers, preferably of Type I glass. Type I glass
is used to manufacture ampoules. It is not clear if there are differences in the glass
composition of the APP and Lavoisier product containers that influenced the rate of
aluminum increase over time in calcium gluconate stored in those containers.
Irrespective of the glass source, using a calcium gluconate solution from a glass
package that has been on the shelf for some time exacerbates the problem of aluminum
contamination.

Switching calcium gluconate from glass to plastic packaging does not remove all
parenteral nutrition component sources of aluminum. Plastic packaged calcium
gluconate contains measurable aluminum (Table 1 and results of this study). Other

11

components of parenteral nutrition solutions and intravenous therapy of neonates are
also contaminated with aluminum. Three of concern are phosphates, heparin, and
albumin. Table 2 contains the aluminum concentrations in phosphates, heparin, and
albumin reported in the publications cited in Table 1. There are reports of aluminum
concentrations in 18 phosphate solutions in which the phosphate concentration is
sufficiently reported to calculate aluminum (in µg) in one mmol of phosphate (2, 17, 22,
25, 28, 30, 33, 34, 41), the phosphate dose to initiate parenteral nutrition per kg patient
body weight (48). The median aluminum concentration of the 18 solutions is 1400 µg/L,
which would deliver 1.4 µg aluminum per mmol phosphate. Compared to the ~ 20 µg of
aluminum from calcium gluconate that would be in parenteral nutrition solution for a 1 kg
neonate (above), calcium gluconate is a greater contributor. The aluminum contribution
from heparin to parenteral nutrition solutions is negligible, given its suggested
concentration in parenteral nutrition solutions is 1 U/mL (48) . As albumin is not a
routine component of parenteral nutrition solutions its contribution compared to calcium
gluconate is not made. However, large, repeated albumin doses might present a
significant amount of aluminum.

The problem of aluminum contamination of calcium gluconate can be largely avoided by
the use of plastic packaging, as has been suggested (20, 40). The present results
support that suggestion.

A concern for products packaged in plastic is the potential release of plasticizers from
the container into the product. The phthalates are of particular concern, especially for
infants. The maximum allowable dose for DEHP by intravenous injection to neonatal
12

infant boys (birth to 28 days of age) is 210 μg/day (50). Based on the typical initial
parenteral calcium dose for a neonate of average weight (3.4 kg), which would be
delivered in ~ 14.6 mL of 10% calcium gluconate, the maximum allowable level of
DEHP in calcium gluconate is ~ 15 μg/mL. None of the samples had > 0.2% of this
level.

The results of the present study, and prior reports of aluminum contamination of calcium
gluconate packaged in glass and plastic, and the lack of phthalate plasticizers in
calcium gluconate packaged in plastic, support the suggestions that glass-packaged
calcium gluconate should be avoided as a component of parenteral nutrition solutions
delivered to patients with impaired kidney function. The recent introduction in the US of
plastic container packaged calcium gluconate should enable the preparation of
parenteral nutrition solutions with considerably reduced aluminum content, to the benefit
of patients with impaired kidney function, including premature neonates.
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Figure legends
Figure 1. Aluminum concentration of calcium gluconate packaged in glass. The values
are from Table 1 with the exclusion of 10,695 reported by (35) and values reported by
(18). Line is best fit of the data points.

Figure 2. Aluminum concentration in 10% calcium gluconate from single lots collected
over time. Values are the mean of the duplicate samples collected on and after the date
of the first sample (time = 0). Note the different Y axis scale for the B. Braun product.
Line is best fit of the results.
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Table 1

Table 1. Reported aluminum concentrations in calcium gluconate.

Source (as stated in the reference)

Aluminum
concentration
(µg/L)

Reference

Packaged in glass
Calcium gluconate 10%

5056

(2)

Calcium, Sandoz

3753

(28)

Calcium gluconate, Lymphomed

2245 (range 2000 to
2586)

Calcium gluconate, Invenex

2592 & 2610

Calcium gluconate, Elkins Sinn

3973 (range 1095 to

(13)

5565)
Calcium gluconate, IMS

3299

Calcium gluconate, American quinine

2286

10% Calcium gluconate, Phoenix

3430

(29)

Calcium gluconate

4850

(30)

Ca gluconate, Lymphomed

2375 (range 2000 to
2750)

(31)

Calcium gluconate

1100 to 5600

(14)

Calcium gluconate 10%, Pharmacie Centrale AP Paris

675 & 1830

Calcium gluconate 10%, Arguettant

1890

Calcium gluconicum, Braun

3825

(3)

Calcium gluconate, Palex

5437

(33)

Calcium gluconate 0.22 mmol/mL, David Bull Labs. Pty. Ltd.

5800

Calcium 10%, Sandoz

4900

Calcium gluceptate 10%

4800

(32)

(34)

Table 1. Reported values of the aluminum concentration in calcium gluconate. (cont.)
Calcium 10%, Braun

4734 & 6243

Calcium 20%, Braun

10,695

Calcium-gluconat 10%, Pharma Hameln

4421

Calcium gluconate 10%, Meram

5940

Calcium gluconate 10%, Aguettant

5940

Calcium gluconate, AP Paris

6130

Calcium gluconate, American Regent

4201 ± 267

(16)

10% Calcium gluconate, Commercial Polfa

4400

(36)

Calcium gluconate 10% (10 ml vial)

5000

Calcium gluconate 10% (100 ml vial)

3000

Calcium gluconate 20% (10 ml vial)

6000

Halex Istar (lot 1)

5621

Halex Istar (lot 2)

6781

Ariston

5960

B. Braun

4530

Elkins Sinn

3987

Calcium gluconate 10%

5621 & 5960

(25)

Calcium gluconate 5%, PCH, Paris, France

680

(17)

Calcium gluconate 10%

2712 (range 2240 to
3040)

(35)

(15)

(37)

(22)

(38)

Calcium gluconate 10%, Hypofarma

9205 & 19,400

(18)

Calcium gluconate

3234

(39)

Calcium gluconate 10% (new)

4910

Calcium gluconate 10% (old)

6150

(40)

Table 1. Reported values of the aluminum concentration in calcium gluconate. (cont.)
Calcium gluconate 100 mg/ml, American Pharmaceutical Partners

2812 (range 1969 to
3495)

Calcium gluconate 100 mg/ml, American Regent

2487 (range 1928 to

(41)

2887)
Calcium gluconate 10%

range: 4000 to 4400
(42)

Calcium gluconate 10%, PISA Farmaceutica

3890

Calcium gluconate 20%

4000 (range 3100 to
4200)

(20)

(21)

Packaged in plastic
Calcium gluconate 10%, Braun

105

Calcium gluconate 20%, Braun

195

Calcium gluconate 10%

27 & 30 (new)
31 & 33 (old)

(37)

(40)

Table 2

Table 2. Reported aluminum concentrations (µg/L) in phosphates, heparin and albumin.

Phosphate

Potassium phosphate 3 M

16,598

Heparin

Albumin

1000 U/mL 684

25% 1822
(2)

5000 U/mL 359
Sodium phosphate 3 M

5056

Potassium phosphate 1 M

486

1296

Potassium phosphate

92 & 2189

25% 914 &

(2069 to 2301)

2364 (1116 to

6 & 2236 (2026

5849)

Sodium phosphate

Reference

10,000 U/mL 468
(28)

(13)

to 2370)
Potassium acid phosphate

1882

Potassium acid phosphate 13.6%

2154

(29)

(30)

(1 M)
Potassium phosphate

2754 (2025 to
7128)

Sodium phosphate

65 (ND* to 284)

Potassium phosphate

90 to 2300

Sodium phosphate

< 5 to 2370

(31)

(14)
5% 164
20% 28

Potassium phosphate

9539

Monopotassium phosphate 1 M

1533

Dipotassium phosphate 1 M

3615

Monosodium phosphate 1 M

1451

(3)

(33)

Table 2. Reported aluminum concentrations (µg/L) in phosphates, heparin and albumin. (cont.)
Potassium acid phosphate 1 M

2387

Potassium dihydrogen phosphate
0.54 g and di- potassium

100 to 25,000
7689

hydrogen phosphate 1.83 g in 10

(34)

U/mL
6 to 31

mL
Potassium phosphate, Braun

18 & 188

Potassium phosphate pfrimmer,

2826 & 3421

5% 90 ± 61

25,000 IE/5 mL

20% 57 ± 45

6288
(16)

Regent
Potassium phosphates, not

(35)

70

Kabi
Sodium phosphates, American

Sodium heparin

9800

commercial
(36)
Sodium potassium phosphates,

13,000 to 41,600

Addiphos Pharmacia
Potassium phosphate, Aster, B.

689 ± 348

Braun, & Fresenius, 2 mEq/mL

5000 IU/mL

20% 94 & 235

481 ± 275
(22)

5000 IU/0.25 mL
Sodium phosphate, Abbott &

568 ± 320

165 ± 27

Geyer, 0.5 M
Potassium phosphate, 2 mEq/mL

988 & 1325

5000 IU/mL

Sodium phosphate, 0.5 mol/L

879 & 933

732 & 738

Dipotassium phosphate 1.7 M

240

20% 149 & 644
(25)
(17)

Sodium heparin

20% 221

1% 108 (range

(range: 195 to

106 to 112)

231)

(38)

Table 2. Reported aluminum concentrations (µg/L) in phosphates, heparin and albumin. (cont.)
Potassium phosphate, American

8250

Pharmaceutical Partners
(39)
Sodium phosphate, American

622

Regent
Potassium phosphate 3 M

4040 & 9972

Sodium phosphate 3 M

29 & 3242

Potassium phosphate, PISA

3780

(41)

Farmaceutica
(20)
Sodium phosphate, PISA

1780

Farmaceutica
Sodium phosphate

4460 (range
4638 to 4809)

* = not detected

(21)

Supplemental Information to: Aluminum and phthalates in calcium gluconate;
contribution from glass and plastic packaging

Materials and Methods:
Materials:
Twenty-five 10 ml glass vials of Calcium Gluconate Injection, USP (APP
Pharmaceuticals, LLC, Schaumburg, IL; Product Code 31110, NDC No. 63323-311-10,
Lot 6005911, Expiration April, 2015), ten 10 ml glass ampoules of Gluconate de
Calcium Lavoisier 10% (C.D.M. Lavoisier, 75017 Paris, France; Lot 2A154, Expiration
September, 2015), and twenty 10 ml plastic ampulles of Calciumgluconat 10% B. Braun
Injektionslösung (B. Braun Melsungen AG – 34209 Melsungen, Deutschland; Lot
12417011; Expiration September, 2015) were obtained in July, 2013. One 10 plastic vial
of Calcium Gluconate Injection, USP (Fresenius Kabi, LLC, Lake Zurich, IL; Product
Code 31110, NDC No. 63323-311-19, Lot 6009399, Expiration March, 2016), was
obtained in May, 2015. EPA Method 506 Phthalates Mixture containing bis(2-ethylhexyl)
adipate, bis(2-ethylhexyl) phthalate (DEHP), butyl benzyl phthalate, di-n-butyl phthalate,
dimethyl phthalate, diethyl phthalate, and di-n-octyl phthalate (Ultra Scientific); an
internal standard mix containing acenaphtene-d10, chrysene-d12, 1,4-dichlorobenzened4, naphthalene-d8, perylene-d12, and phenanthrene-d10 (Restek); and an EPA
Method 3500 (SW-846) and CLP–Semi-Volatiles Base/Neutrals Surrogates mixture
containing 2-fluorobiphenyl, nitrobenzene-d5, and p-terphenyl-d14 (Restek) were
obtained from VWR.
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Methods:
Sample collection:
Approximately half of the 10 ml calcium gluconate contents of individual containers from
APP Pharmaceuticals and B. Braun was clean poured into duplicate seven ml
perfluoroalkoxy alkanes (PFA) vials (Savillex, Eden Prairie, MN) at ~ 1.5 month
intervals. Approximately half of the 10 ml contents of ampoules from C.D.M. Lavoisier
was clean poured into duplicate seven ml PFA vials at ~ 1.5 month intervals initially,
then ~ at three month intervals. Approximately half of the 10 ml contents of the
Fresenius Kabi product was clean poured into duplicate seven ml PFA vials September
8, 2015. Sample transfer was conducted in a Class 100 laminar flow hood. The PFA
vials had been pre-cleaned by soaking in 10% nitric acid then 5 mm EDTA, and triple
rinsed with 18.2 MΩ-cm water. Water (18.2 MΩ-cm) from a Barnstead NANOpure water
polishing system, stored in a 500 ml FEP bottle that had been triple cleaned with trace
metal grade nitric acid, was clean-poured into duplicate PFA vials on many of the same
occasions calcium gluconate samples were transferred, to serve as a blank. All samples
before and after transfer to PFA vials were stored at room temperature throughout the
study.

Aluminum quantification in calcium gluconate solutions by ICP-MS:
Immediately prior to analysis, samples were heated to solubilize precipitation and then
diluted two-hundred-fold with 1% (v/v) concentrated ultra-pure nitric acid. Results were
compared to a standard curve created from an Inorganic Ventures (Christiansburg, VA,
USA) multi-element ICP-MS standard. To validate the calibration curve, a standard of
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known concentration was prepared from a multi-element standard of a different lot
number and analyzed as an unknown. Two samples were diluted and analyzed a
second time as sample dilution replicates. Spike recovery was determined by adding 10
µL of the 10 mg/L calibration standard to two 10 mL samples, adding 10 µg/L aluminum.
Scandium was added as the internal standard to all samples and standards for the
aluminum analyses at the same concentration (approximately five µg/L). The instrument
detection limit was calculated as three times the standard deviation of the eleven
reagent blanks. Care was taken to minimize metal contamination, including use of
metal-free centrifuge tubes, trace metal grade nitric acid, and 18.2 MΩ-cm water. All
dilution procedures were conducted in a class 100 laminar flow hood. Samples were
analyzed by ICP-MS (Agilent 7500cx, Santa Clara, CA, US).

Aluminum analysis of glass vials by laser ablation ICP-MS:
A glass vial that contained Calcium Gluconate Injection, USP from APP
Pharmaceuticals and a glass ampoule that contained Gluconate de Calcium from
Lavoisier were wrapped in paper and shattered using a hammer. Samples from the
bottom of each vial were collected and rinsed thoroughly with deionized water. The
samples were them mounted on microscope slides using double sided tape with the
inside surface of the bottom of the vials facing up. The samples were analyzed using a
213 nm laser ablation system (CETAC Technologies LSX-213, Omaha, NE, USA)
coupled to an inductively coupled plasma mass spectrometer (Agilent Technologies
7500CX, Santa Clara, CA, USA). Duplicate samples from each vial were ablated with
100 laser shots at a frequency of 20 Hz within a 200 µm spot. Standardization was
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performed by ablating standards with known aluminum concentrations in a calcium
carbonate matrix in the same manner. These standards were prepared by mixing a
known mass of aluminum contained within an ICP-MS standard solution (Inorganic
Ventures, Christiansburg, VA, USA) with a known mass of calcium carbonate, drying
the mixture, and pressing it into pellets with a pellet press. We were not able to make or
obtain standards with a glass matrix that had known aluminum concentrations.
Consequently, although the numbers are precise, they may not be accurate because
laser ablation is highly matrix dependent. The true aluminum concentration may be
different by as much as 10-fold. The aluminum concentration in the glass of the glass
vial from APP was 2082 ± 170 (SD) mg/kg (~ 0.2%) and in the glass of the glass
ampoule from Lavoisier: 2224 ± 228 (SD) mg/kg (~ 0.2%). These results indicate there
was no significant difference in the aluminum concentration between these two
containers, but must not be cited as accurate determinations of aluminum
concentration. Reports of the aluminum concentration in glass vials include 5.8% Al2O3
(or 3.1% Al) in Type I USP borosilicate hard glass and 1.9% Al2O3 (or 1% Al) in Type II
USP soft glass (1), 0.61 to 3.01% aluminum (2), and 5% Al2O3 (or 2.6% Al) in Type I
USP glass (3).

Phthalate analysis in calcium gluconate solutions by gas chromatography – mass
spectrometry:
A method was developed based on a modification of EPA method 8270D that separated
the seven components of the phthalates mixture, with retention times from 12.95 to
25.12 minutes. DEHP eluted at 23.65 minutes. The method also separated the
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phthalates from the six internal standard components, which had retention times from
6.74 to 26.49 minutes, and the three surrogates, which had retention times from 7.85 to
20.92 minutes. A calibration curve was prepared containing 0.1, 1.0, 2.5, 5.0, 7.5, and
10 ppm phthalates. Five blanks were prepared (water, water exposed to pipette tip from
the lot used to prepare the dilutions of calcium gluconate for ICP-MS aluminum
quantification [above], Calcium Gluconate Injection USP, Calcium Gluconate Injection
USP in PFA vial, and Calcium Gluconate Injection USP exposed to pipette tip).
Phthalate recovery was determined from water and Calcium Gluconate Injection USP in
PFA vials, by addition of 5 ppm phthalates. Samples of 10% calcium gluconate from
APP Pharmaceuticals, Lavoisier, and B. Braun from the last collection date (August 25,
2015) and the Fresenius Kabi sample were analyzed for their phthalate content. Five µL
of 1000 ppm surrogate mix was added to the blanks, spiked samples, and 10% calcium
gluconate samples (four to five ml) which were then extracted by adding three ml
dichloromethane, shaken vigorously for five minutes, then transferring the organic layer
to a separate vial. The extraction step was repeated and the extracts were combined
and evaporated under a gentle stream of nitrogen to near dryness, the vial was rinsed
and brought to a final volume of one ml with dichloromethane. Two µL of 2000 ppm
internal standard mix was added to each of the extracts and calibration curve
components. The samples were analyzed on a Varian CP-3800 GC with a Varian
Saturn 2200 MS.

Phthalate analysis in leachates from plastic containers by gas chromatography – mass
spectrometry:
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The B. Braun plastic container that provided the last measured sample, on August 25,
2015, and the Fresenius Kabi plastic container were used to determine if phthalates
would leach from the plastic. A portion of the bottom of each container was removed
and weighed (B. Braun 0.311 g; Fresenius Kabi 0.371 g) and placed in 24 ml vials with
five ml of dichloromethane. The vials were agitated by sonication and vortex mixing for
10 minutes. One ml of the extract was transferred to an autosampler vial adding two µL
of internal standard mix. Samples were analyzed by GC-MS as described above for the
detection of phthalates.
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